pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
MOUNJARO · news · pharmadog
← back to MOUNJARO
News mentioning MOUNJARO
155
stories
1d
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
biopharma dive
3d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
3d
STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
stat
6d
STAT+: Up and down the ladder: The latest comings and goings
stat
6d
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
stat
6d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
7d
Deep dive: Cardiovascular calamities and catalysts
biospace
7d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
7d
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
stat
8d
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
stat
8d
STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
stat
8d
The U.S. may soon lose measles elimination status
stat
8d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
9d
STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
stat
9d
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
stat
10d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
10d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
10d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
10d
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
stat
10d
Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...
raps
13d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
14d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
15d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
15d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
16d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
20d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
21d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
22d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
← prev
page 1 of 6
next →